Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 3Diarrhea 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 31Nivolumab 12Cyclophosphamide 10fludarabine 9aldesleukin 8atezolizumab 7durvalumab 6Magnetic Resonance Spectroscopy 6Trastuzumab 5Specimen Handling 5Paclitaxel 5Ipilimumab 5Docetaxel 5Biopsy 5fludarabine phosphate 4Radiotherapy 4Interleukin-2 4Gene Expression Profiling 4Carboplatin 4tisotumab vedotin 3cemiplimab 3aflibercept 3Polymerase Chain Reaction 3Immunoglobulin G 3Early Intervention, Educational 3Cisplatin 3Bevacizumab 3tremelimumab 2tislelizumab 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Octreotide × Genitourinary × Clear all
NCT00033605 2016-07-13

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Alliance for Clinical Trials in Oncology

Phase 3 Completed
130 enrolled
GastrointestinalGenitourinaryGynecologicSarcoma

Uterine Cervical Neoplasms, Diarrhea, Fallopian Tube Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vaginal Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡